On September 15th Soligenix, Inc. (SNGX) announced that its Phase 3 clinical trial study of orBec to be stopped because it is highly unlikely to achieve the predetermined primary objective of efficacy based on the interim results. Disappointed news for Soligenix after all these years of orBec’s studies, isn’t it? Market reaction was expected – […]